Author + information
- Received July 30, 2008
- Revision received November 19, 2008
- Accepted December 16, 2008
- Published online March 1, 2009.
- Ehtisham Mahmud, MD, FACC⁎,⁎ (, )
- John A. Ormiston, MBChB†,
- Mark A. Turco, MD, FSCAI‡,
- Jeffrey J. Popma, MD§,
- Neil J. Weissman, MD∥,
- Charles D. O'Shaughnessy, MD¶,
- Tift Mann, MD#,
- Jack J. Hall, MD⁎⁎,
- Thomas F. McGarry, MD††,
- Louis A. Cannon, MD‡‡,
- Mark W.I. Webster, MD§§,
- Lazar Mandinov, MD∥∥ and
- Donald S. Baim, MD∥∥
- ↵⁎Reprint requests and correspondence:
Dr. Ehtisham Mahmud, UC San Diego Medical Center, Cardiovascular Catheterization Labs, 200 West Arbor Drive, San Diego, California 92103-8784
Objectives The aim of this study was to assess the relative efficacy and safety of the second-generation TAXUS Liberté paclitaxel-eluting stent (PES) in patients with and without diabetes mellitus.
Background Diabetic patients suffer from accelerated atherosclerosis and increased risk of restenosis after coronary interventions; however, prior data suggest that PES might blunt this effect, providing equal benefit in diabetic and nondiabetic patients.
Methods A pooled analysis of all 4 TAXUS ATLAS studies was conducted that included 413 diabetic and 1,116 nondiabetic subjects treated with the TAXUS Liberté stent for de novo coronary lesions. Angiographic and intravascular ultrasound outcomes at 9 months and clinical outcomes at 9 and 12 months were compared in patients with and without diabetes. Propensity score and multivariate adjustments were performed to correct for baseline differences.
Results In-stent angiographic restenosis (13.0% vs. 9.6%, p = 0.12), late luminal loss (0.40 mm vs. 0.38 mm, p = 0.58), and intimal hyperplasia (14.8% vs. 13.4%, p = 0.29) were similar for diabetic and nondiabetic subjects. After propensity adjustment, 12-month target lesion revascularization rates were similar for diabetic and nondiabetic subjects (6.4% vs. 4.7%, p = 0.18), with no differences in mortality, myocardial infarction, or stent thrombosis. However, the rate of target vessel revascularization (TVR) was higher for diabetic subjects due to increased TVR outside the target lesion (TVR Remote).
Conclusions Similar clinical, angiographic, and intravascular ultrasound outcomes were observed for both diabetic and nondiabetic subjects treated with TAXUS Liberté, suggesting that this PES attenuates the effect of diabetes on restenosis after percutaneous coronary intervention, yielding comparable efficacy and safety in diabetic and nondiabetic patients. (TAXUS ATLAS; NCT00371709, NCT00371423, NCT00371748, and NCT00371475)
This study was supported by Boston Scientific Corporation, Natick, Massachusetts. The authors wish to disclose the following conflicts of interest related to Boston Scientific: research grant support (to Drs. Mahmud, Turco, Popma, Weissman, O'Shaughnessy, and Webster); consulting fees/honoraria (to Drs. Ormiston, O'Shaughnessy, and Cannon); advisory board (to Drs. Ormiston, Turco, Popma, O'Shaughnessy, and Cannon); Speakers' Bureau (to Drs. Turco, Popma, O'Shaughnessy, and Cannon); stock options/equity interest (to Drs. Mandinov and Baim); and salary/full-time employee (to Drs. Mandinov and Baim).
- Received July 30, 2008.
- Revision received November 19, 2008.
- Accepted December 16, 2008.
- American College of Cardiology Foundation